摘要
目的为《药品管理法》再修订提供立法思路和建议。方法通过对初修订的《药品管理法》与当时药事立法间联系的考察,思考《药品管理法》再修订时应当如何参考当前的药事立法成果。结果与结论《药品管理法》再修订应关注如下问题:急需药品执行特别审批程序、中药、新药注册、药用原辅料、医疗机构制剂、药品进口、假劣药、药品包装、药价、药品广告和药品监督等。
Objective To provide legislative approach and advice for the revision of Pharmaceutical Administration Law.Methods To think about ways to refer to the achievements of the current pharmaceutical legislation while Pharmaceutical Administration Law is re-amended by reviewing the relationship between the first amended Pharmaceutical Administration Law and the earlier pharmaceutical legislation.Results and Conclusion The following problems should be emphasized when Pharmaceutical Administration Law is re-amended： special examination and approval procedures for urgently needed pharmaceuticals,traditional Chinese medicine,new pharmaceuticals registration,raw and supplementary pharmaceutical materials,medicinal preparations,import of pharmaceuticals,the fakery or inferior quality of the pharmaceuticals,packaging of pharmaceuticals,prices of pharmaceuticals,advertisements of pharmaceuticals,supervision over pharmaceuticals.
出处
《中国药事》
CAS
2010年第10期949-956,共8页
Chinese Pharmaceutical Affairs
关键词
药事立法
《药品管理法》
再修订
pharmaceutical legislation
Pharmaceutical Administration Law of the People＇s Republic of China
re-amendment
